| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
Tenovin-2 targets sirtuin deacetylases, specifically the SIRT1, SIRT2, and SIRT3 isoforms. While its exact binding affinity is not specified in the provided results, it is structurally and functionally related to Tenovin-6, which inhibits these enzymes. By inhibiting sirtuins, Tenovin-2 can modulate the acetylation status of various proteins, including p53, thereby affecting cell cycle regulation and apoptosis.
|
|---|---|
| ln Vitro |
In vitro, Tenovin-2 is known to activate p53 transcriptional activity. Based on the activity of the related compound Tenovin-6, it is expected to inhibit SIRT1, SIRT2, and SIRT3 deacetylase activities, leading to increased acetylation of p53 and other substrates. This results in the activation of p53-dependent transcription and subsequent effects on cell cycle arrest and apoptosis.
|
| ln Vivo |
Specific in vivo data for Tenovin-2 are not detailed in the provided search results. As a research compound, its application is primarily in in vitro systems to study the role of sirtuins in various cellular processes. Its in vivo effects would be predicted based on its mechanism of action, but such data are not extensively documented.
|
| Enzyme Assay |
Non-cellular enzyme assays for Tenovin-2 involve measuring its inhibition of sirtuin deacetylase activity. These assays use recombinant SIRT enzymes and a fluorogenic or radiolabeled acetylated peptide substrate. The extent of deacetylation is measured in the presence of varying concentrations of the inhibitor to determine its IC50, as is done for related compounds like Tenovin-6.
|
| Cell Assay |
In vitro cell-based assays for Tenovin-2 are conducted using various cell lines to assess its effects on p53 activity and downstream signaling. Cells are treated with the compound, and the acetylation status of p53 and other proteins, as well as the expression of p53 target genes, are measured by Western blotting and qPCR. Cell cycle and apoptosis assays are also performed to evaluate functional outcomes.
|
| Animal Protocol |
Specific in vivo animal study protocols for Tenovin-2 are not detailed in the provided search results. As a research compound, it is primarily used in in vitro experiments to study sirtuin biology. If used in vivo, it would likely be administered via intraperitoneal injection, but such applications are not extensively documented.
|
| ADME/Pharmacokinetics |
Tenovin-2 has a molecular weight of 397.53 g/mol and a molecular formula of C22H27N3O2S. It is soluble in DMSO. Its pharmacokinetic properties, such as half-life and bioavailability, are not extensively detailed in standard summaries. It is a research compound intended for laboratory use.
|
| Toxicity/Toxicokinetics |
Comprehensive toxicological data for Tenovin-2 are limited as it is a research compound. It is intended for laboratory use only and is not for human consumption. As with all research chemicals, appropriate safety precautions should be taken when handling Tenovin-2.
|
| Additional Infomation |
Tenovin-2 is a research compound used to study the role of sirtuin deacetylases, particularly in the context of p53 regulation and apoptosis. It is a tool for investigating the effects of sirtuin inhibition on cellular processes such as aging, metabolism, and cancer. It is not an approved drug.
|
| Molecular Formula |
C22H27N3O2S
|
|---|---|
| Molecular Weight |
397.53
|
| Exact Mass |
397.182
|
| CAS # |
666211-30-9
|
| PubChem CID |
1017523
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.2±0.1 g/cm3
|
| Index of Refraction |
1.631
|
| LogP |
3.85
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
28
|
| Complexity |
555
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S=C(NC1C=CC(=CC=1)NC(C(C)C)=O)NC(C1C=CC(=CC=1)C(C)(C)C)=O
|
| InChi Key |
BRWAJDBGZFTAQH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H27N3O2S/c1-14(2)19(26)23-17-10-12-18(13-11-17)24-21(28)25-20(27)15-6-8-16(9-7-15)22(3,4)5/h6-14H,1-5H3,(H,23,26)(H2,24,25,27,28)
|
| Chemical Name |
4-(1,1-dimethylethyl)-N-[[[4-[(2-methyl-1-oxopropyl)amino]phenyl]amino]thioxomethyl]-
|
| Synonyms |
Tenovin-2Tenovin 2Tenovin2
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5155 mL | 12.5777 mL | 25.1553 mL | |
| 5 mM | 0.5031 mL | 2.5155 mL | 5.0311 mL | |
| 10 mM | 0.2516 mL | 1.2578 mL | 2.5155 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
